Abstract
Background: Long Interspersed Nuclear Element-1 (LINE1) retrotransposons, High Mobility Group Box 1 (HMGB1), and Uterine Sensitization-Associated Gene 1 (USAG1, also known as SOSTDC1) represent three powerful but potentially lethal biological systems whose coordinated pharmacological activation has never before been achieved.
Objective: To investigate the coordinated regulation of LINE1, HMGB1, and USAG1 by Metadichol nanoemulsion in human peripheral blood mononuclear cells (PBMCs) and elucidate the systems-level mechanisms enabling safe activation.
Methods: Human peripheral blood mononuclear cells were treated with Metadichol at concentrations ranging from 1 pg/mL to 100 ng/mL for 24 hours. Gene expression was quantified by reverse transcription polymerase chain reaction (RT-PCR) using the 2^-ΔΔCt method, with glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as the reference gene.
Results: Metadichol induced unprecedented, coordinated upregulation at the mRNA level: LINE1 (3.41–17.99-fold, maximum at 100 pg/ml), HMGB1 (2.27–6.02-fold, maximum at 100 ng/ml), and USAG1 (3.39–8.06-fold, maximum at 100 ng/ml). Western blot analysis confirmed protein-level upregulation of all three targets, with LINE1 ORF1p reaching 1.90-fold, USAG1 reaching 1.40-fold, and HMGB1 showing 1.10-fold increase. The marked mRNA-to-protein attenuation (LINE1: up to 16.1×; HMGB1: up to 5.5×; USAG1: up to 6.3×) indicates active post-transcriptional and post-translational braking. Strong positive correlation between LINE1 and USAG1 mRNA expression (r=0.89) demonstrated coordinated regulation. This represents the first pharmacological achievement of simultaneously activating all three systems with dual mRNA and protein validation. Notably, this induction was cell-type selective: across six human cancer cell lines (A549, HCT116, HeLa, HepG2, U-87 MG, FaDu), LINE-1, USAG1, and HMGB1 mRNA remained essentially unchanged (mean fold change ≈ 1.0; maximum 1.65–1.84-fold), an order of magnitude below the PBMC response.
Conclusions: Metadichol orchestrates a systems-level response integrating innate immunity (LINE1), inflammatory amplification (HMGB1), and tumor suppression (USAG1) within a comprehensive protective framework involving nuclear receptors, sirtuins, FOXO factors, Klotho, vitamin C-TET enzymes, and circadian regulators. Crucially, western blot validation demonstrates that large transcript-level inductions are actively dampened at the protein level—confirming that coordinated post-transcriptional braking mechanisms prevent runaway effector accumulation. This two-tier mRNA-plus-protein dataset establishes the mechanistic safety of Metadichol’s controlled immuno-stimulation and opens new therapeutic avenues for cancer prevention and immune enhancement. The robust activation in primary immune cells alongside a neutral profile in cancer cells demonstrates cell-type-selective, context-dependent action—an ideal safety signature for immune enhancement.